Denali Therapeutics stock rockets into record territory after Biogen investment and collaboration

Shares of Denali Therapeutics Inc. DNLI, 36.53% rocketed 29% into record territory in premarket trading Thursday, after Biogen Inc. BIIB, 0.06% announced a $465 million equity investment as part of a collaboration on Denali's treatment for Parkinson's disease.